现有和新兴的GLP-1受体激素治疗:糖尿病视网膜病变查的分支
George Iype Varughese1, Sarita Jacob2,3,4,5
1University Hospitals of North Midlands NHS Trust, Stoke-on-Trent, North Staffordshire, UK.
概括
葡萄糖类-1 (GLP-1) 受体激动剂可以改善2型糖尿病的治疗,但可以暂时恶化糖尿病视网膜病变 (DR). 由于药物短缺,处方医生必须在重新开始治疗之前重新评估DR状态.
科学领域:
- 内分泌学 在内分泌学.
- 眼科医生 眼科 眼科
- 药理学 药理学是指药理学的学科.
背景情况:
- 葡萄糖类-1 (GLP-1) 受体激活剂改变了2型糖尿病 (T2DM) 管理,显著降低了心血管风险和控制了血糖.
- 一个已知的,但往往被忽视的GLP-1受体激动剂的作用是由于葡萄糖水平的快速提高而导致先前存在的糖尿病视网膜病变 (DR) 的过渡性早期恶化.
- 目前全球GLP-1受体激动剂短缺,预计将在2024年中断治疗,可能导致血糖控制 (HbA1c) 恶化和DR进展.
研究的目的:
- 要突出处方者意识到随着GLP-1受体激动剂启动而恶化的过渡性糖尿病视网膜病变 (DR) 的可能性的关键需要.
- 强调目前GLP-1受体激动剂缺乏对2型糖尿病患者的血糖控制和DR进展的影响.
- 为医疗保健提供者提供建议,在重新开始GLP-1受体激动剂治疗之前,需要重新评估患者当前的DR状态.
主要方法:
- 对GLP-1受体激素对血糖控制和糖尿病视网膜病变的影响现有文献的综述.
- 分析因药物短缺而导致治疗中断的临床影响.
- 基于当前证据和预期的恢复治疗的临床实践建议.
主要成果:
- GLP-1受体激动剂对T2DM和心血管风险降低是有效的.
- 短暂的DR恶化是一个已知的悖论,与快速降低葡萄糖相关.
- 治疗中断可能导致疾病进展,需要在恢复治疗时仔细监测.
结论:
- 处方者必须保持警,在启动或恢复GLP-1受体激动剂治疗时,对潜在的DR改变保持警.
- 目前的药物短缺强调了主动患者管理和对血糖控制和DR状态的监测的重要性.
- 与眼科查服务的密切合作至关重要,以确保在治疗中断期间和之后的最佳患者结果.
相关概念视频
01:24Glucagon-like Receptor Agonists
321
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
321
01:06Oral Hypoglycemic Agents: Glinides
154
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
154
01:23Dipeptidyl Peptidase 4 Inhibitors
184
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
184
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
196
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
196
01:15Diabetes: Management and Pharmacotherapy
277
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
277
01:22Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K